|
||||||
|
APRIL 30 - MAY 3 2008 PRAGUE, CZECH REPUBLIC |
||||||
|
|
||||||
|
Results of evaluation of the congress |
||||||
| Legend: | 5=excellent | 4=good | 3=average | 2=below average | 1=poor | |
|
|
||||||
|
title lecture |
content | presentation |
| Congress session 1 | ||
| - Mood changes/depression | 4,14 | 3,89 |
| - Weight changes | 4,00 | 4,07 |
| - Bone Mineral Density (BMD) | 4,35 | 4,42 |
| - Breakthrough bleeding | 3,91 | 4,00 |
| - How often and why do women discontinue their contraceptive method? Results from a French population-based survey | 4,39 | 4,53 |
| - Comparison of patients from high risk population with vs, without thrombotic events while exposed to hormonal contraception | 4,11 | 3,86 |
| Congress session 2 | ||
| - WHO Global STI epidemiology update | 4,00 | 3,96 |
| - Testing for STIs in family planning setting - How to make it simple? | 3,74 | 3,74 |
| - Guidelines for HPV DNA testing - To test or not to test? | 3,71 | 3,43 |
| - Genital Chlamydial Infection: has the risk for tubal factor infertility and adverse pregnancy outcome been exaggerated? | 3,92 | 3,93 |
| - To screen or not to screen...are current guidelines for screening all women for Chlamydia under age 25 being followed in primary care and at family planning clinics? | 3,65 | 3,53 |
| - First sex: an opportunity of a lifetime for HIV/AIDS prevention | 3,55 | 3,48 |
| Congress session 3 | ||
| - IUD/IUS in nulliparous women | 3,63 | 3,66 |
| - Management of IUD/IUS in special clinical conditions: emergency contraception, actinomyces, HIV, dysplasia, cancers... | 3,77 | 3,54 |
| - Non-contraceptive benefits | 4,24 | 4,48 |
| - Long-term use/use beyond recommended time | 3,91 | 3,87 |
| - The Swing IUS: innovative design for intrauterine contraception | 4,12 | 4,17 |
| - Contraception in the postnatal period | 3,50 | 3,53 |
| Congress session 4 | ||
| - The WHO family planning cornerstones: a living testimony to the power of partnership | 4,61 | 4,23 |
| - Implementation of family planning guidelines in Europe - adoption and adaptation | 4,38 | 4,61 |
| - Recommended changes in practice | 4,50 | 4,47 |
| Congress session 5 | ||
| - The challenge of post-abortion contraception | 4,23 | 4,09 |
| - Follow-up after induced abortion: current practice and evidence | 4,47 | 4,23 |
| - Access to safe abortion: legal and other obstacles | 3,36 | 3,08 |
| - A comparison of two dosages of buccal Misoprostol following Mifepristone for early medical abortion | 3,33 | 3,67 |
| - Expanding options for in-the-mouth Misoprostol administration following Mifepristone in medical abortion | 3,57 | 4,00 |
| Forum 2 | ||
| - Sexual education, sexual health training needs | 4,36 | 4,29 |
| Forum 3 | ||
| - What is required/minimal criteria/what should be examined before prescribing | 3,88 | 4,06 |
| Keynote lecture 1 | ||
| - HPV vaccination | 4,21 | 4,13 |
| Keynote lecture 2 | ||
| - Risk of DVT with new molecules | 4,13 | 4,08 |
| Keynote lecture 3 | ||
| - New developments in contraception | 4,45 | 4,41 |
| Plenary session 1 | ||
| - Metabolic benefits | 3,96 | 4,02 |
| - Menorrhagia | 3,93 | 3,98 |
| - Cycle-related symptoms | 4,25 | 4,35 |
| Plenary session 2 | ||
| - Passion, love and relationship | 4,48 | 4,54 |
| - Hormones and sexual behaviour | 4,22 | 4,19 |
| - Sexual problems in the family planning consultation-what to do | 4,21 | 4,11 |
|
|
